Kwok Pang – VJRegenMed

Standardizing digitization processes in the CGT industry

Simon Ng — Mon, 14 Feb 2022 17:40:24 +0000

Kwok Pang, COO, Autolomous, London, UK, gives an overview of digitization tools in the cell and gene therapy (CGT) industry. The advent of process analytics within the field of digitization has enabled the exchange of data between different systems, and integration of various platforms has brought many advantages. He additionally highlights the value of an integrated value chain for GCT developers. This interview took place at Advanced Therapies Week 2022.

Accelerating manufacturing with real-time data analysis

Simon Ng — Mon, 14 Feb 2022 17:40:23 +0000

Kwok Pang, COO, Autolomous, London, UK, describes practical efforts in implementing real-time data analysis to optimize the value chain in the cell and gene therapy (CGT) space. Processing the data in real-time enables manufacturing processes to be scaled-up as decisions can be made instantaneously. Manufacturing costs can additionally be lowered as a result, where increased density of the relevant infrastructure in a given area can increase efficiency. This interview took place at Advanced Therapies Week 2022.

Optimizing CGT manufacturing processes with digitalization

Simon Ng — Thu, 03 Feb 2022 10:27:38 +0000

Kwok Pang, COO, Autolomous, London, UK, discusses the relevance of the concept of Industry 4.0 within the cell and gene therapy (CGT) space, highlighting the advantages of process analytical technologies (PAT). To scale up manufacturing in the CGT industry, it is critical to understand the data in order to optimize manufacturing processes. However, many technologies in the CGT space have limited data exchange capabilities. PATs enable monitoring the data in real-time, which allows us to have a better understanding of the process. This interview took place at Advanced Therapies Week 2022.

Establishing Chain of Identity & Chain of Custody standards in CGT manufacturing

Simon Ng — Thu, 03 Feb 2022 10:27:37 +0000

Kwok Pang, COO, Autolomous, London, UK, comments on Autolomous’ recent strategic partnership with Vineti, which aims to deliver supply chain management solutions in the cell and gene therapy (CGT) space by creating a seamless end-to-end CGT delivery process. Mr Pang explains that integrating the chain of identity (CoI) and chain of custody (CoC) will allow any issues to be identified and resolved during the manufacturing process, which will result in an increased transparency and improve the exchange of information to and from stakeholders. This interview took place at Advanced Therapies Week 2022.

Novel technologies for the digitization of the advanced therapy supply chain

admin_vjr_user — Sat, 06 Nov 2021 09:39:19 +0000

Kwok Pang, COO, Autolomous, London, UK, describes a range of digital supply chain technologies being developed by Autolomous that aim to help advanced therapy manufacturers to scale their operations. For example, AutoloMATE Assist supports the batch verification and review process for advanced therapies to drive efficiency and accelerate the release of manufactured products to patients. In addition, AutoloMATE Clock aims to utilize technologies such as geofencing to help digitise the many aspects of manufacturing scheduling, including manufacturing operator resource management, equipment validation and clean room availability. This interview took place at the Advanced Therapies Congress & Expo 2021.

Simplifying analytical testing to drive POC manufacture

admin_vjr_user — Sat, 06 Nov 2021 09:39:16 +0000

Kwok Pang, COO, Autolomous, London, UK, considers challenges facing the move toward point-of-care manufacturing of advanced therapies and explains the need to simplify the complex analytical testing required to quantify advanced therapies products. He highlights that reliance on complex methods such as flow cytometry, which currently requires a large amount of operator training and experience, is untenable when moving toward a larger scale, point-of-care model and highlights the importance of process simplification and standardization, which he believes can be achieved through industry collaboration. This interview took place at the Advanced Therapies Congress & Expo 2021.

Strategies to facilitate point-of-care manufacture

admin_vjr_user — Thu, 04 Nov 2021 18:02:42 +0000

Kwok Pang, COO, Autolomous, London, UK, discusses strategies to overcome key supply chain challenges associated with the delivery of advanced therapy medicinal products (ATMPs) into healthcare systems. He highlights the need to simplify processes for manufacturing quality analytics in order to facilitate point-of-care ATMP manufacturing. He explains the importance of developing methods to digitalize batch manufacturing records to better monitor the consistency of product manufacture across different locations. This interview took place at the Advanced Therapies Congress & Expo 2021.

Developing manufacturing systems for cell and gene therapies

admin_vjr_user — Thu, 04 Nov 2021 18:02:41 +0000

Kwok Pang, COO, Autolomous, London, UK, gives an overview of the work conducted at Autolomous, a software and technology provider for cell and gene therapy (CGT) developers. He describes ongoing UK government-supported projects including the development of a prototype IT system to streamline communications between the clinic and manufacturing processes to optimize the ordering of advanced therapy medicinal products by the UK NHS. He also describes the ongoing development of systems to help manage the high volume of data and regulatory information produced during the batch certification of cell therapies. This interview took place at the Advanced Therapies Congress & Expo 2021.

Integrating electronic software solutions into healthcare systems

Simon Ng — Thu, 21 Oct 2021 17:14:27 +0000

Kwok Pang, COO, Autolomous, London, UK, explains the challenges involved with integrating electronic software solutions for the management of critical manufacturing data for cell and gene therapies into healthcare systems. He describes an initiative that aims to develop and implement a UK NHS-owned digital system that integrates with manufacturer software in order to enhance the management of patient data, clinical samples and the ordering of advanced therapies by the NHS. He highlights the need for uniformity across the sector in the technologies, standards and methods used for information exchange. This interview took place at the Advanced Therapies Congress & Expo 2021.